RxDoctor Payments Data

Damon Greven, NP

Nurse Practitioner · Auburn, INNPI 1245428366

Payments from drug & device makers

$714in general payments, 2019–2025

Across 14 payments — averaging $51.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$250
  • Paratek Pharmaceuticals, Inc.$125
  • UCB, Inc.$117
  • Teva Pharmaceuticals USA, Inc.$116
  • Sunovion Pharmaceuticals Inc.$76
  • Mylan Specialty L.p.$16
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$714100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$714 in reported general payments places this provider in the 65th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$189,513
Medicare patients
152
Services billed
2,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$77,715
TrulicityDulaglutide76$40,783
MyrbetriqMirabegron169$40,098
JardianceEmpagliflozin88$27,556
GemtesaVibegron91$22,862
FarxigaDapagliflozin Propanediol62$17,860
OzempicSemaglutide14$14,395
XareltoRivaroxaban39$11,428
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog74$11,420
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,310
RexultiBrexpiprazole12$11,216
TradjentaLinagliptin40$10,763
GlyxambiEmpagliflozin/Linagliptin30$8,719
XifaxanRifaximin11$8,275
Janumet XrSitagliptin Phos/Metformin Hcl23$6,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$250$17,86062 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Auburn

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →